Hosted on MSN21d
Guggenheim Initiates Coverage of Compass Therapeutics (CMPX) with Buy Recommendation
The projected annual revenue for Compass Therapeutics is 9MM ... in CMPX by 13.25% over the last quarter. Enavate Sciences GP holds 7,788K shares representing 5.66% ownership of the company.
ETF Daily News21d
Compass Therapeutics (NASDAQ:CMPX) Coverage Initiated at Guggenheim
Enavate Sciences GP LLC acquired a new stake in shares of Compass Therapeutics in the 4th quarter valued at $11,293,000. Tang Capital Management LLC raised its stake in Compass Therapeutics by 225 ...
Analysts Set Compass Therapeutics, Inc. (NASDAQ:CMPX) Price Target at $11.38
Compass Therapeutics, Inc. (NASDAQ:CMPX – Get Free Report) has earned an average recommendation of “Moderate Buy” from the nine ratings firms that are covering the firm, Ratings reports. Two analysts ...